384 related articles for article (PubMed ID: 33538058)
1. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
Khanna D; Zhao C; Saggar R; Mathai SC; Chung L; Coghlan JG; Shah M; Hartney J; McLaughlin V
Arthritis Rheumatol; 2021 May; 73(5):837-847. PubMed ID: 33538058
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M; Esatoglu SN; Kilickiran Avci B; Hatemi G
Intern Emerg Med; 2024 Apr; 19(3):731-743. PubMed ID: 38378970
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Kuang HY; Li Q; Du HA; Chen M; Yin YH
Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
[TBL] [Abstract][Full Text] [Related]
5. 10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry.
Chen X; Quan R; Qian Y; Yang Z; Yu Z; Zhang C; Yang Y; Zhang G; Shen J; Wang Q; Gu Q; Xiong C; Jing X; Han H; He J
Rheumatology (Oxford); 2023 Nov; 62(11):3555-3564. PubMed ID: 36912696
[TBL] [Abstract][Full Text] [Related]
6. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.
Ngian GS; Stevens W; Prior D; Gabbay E; Roddy J; Tran A; Minson R; Hill C; Chow K; Sahhar J; Proudman S; Nikpour M
Arthritis Res Ther; 2012 Oct; 14(5):R213. PubMed ID: 23039366
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Pan J; Lei L; Zhao C
Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
[TBL] [Abstract][Full Text] [Related]
11. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
13. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
14. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study.
Wang J; Wang Y; Li X; Huang Y; Sun X; Wang Q; Zhang M
BMC Pulm Med; 2020 Oct; 20(1):272. PubMed ID: 33076877
[TBL] [Abstract][Full Text] [Related]
15. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data.
Thoreau B; Mouthon L
Autoimmun Rev; 2024 Apr; 23(4):103506. PubMed ID: 38135175
[TBL] [Abstract][Full Text] [Related]
18. Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases.
Arvanitaki A; Giannakoulas G; Triantafyllidou E; Pagkopoulou E; Boutou A; Garyfallos A; Karvounis H; Dimitroulas T
Rheumatol Int; 2021 Jul; 41(7):1289-1298. PubMed ID: 33978819
[TBL] [Abstract][Full Text] [Related]
19. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
[TBL] [Abstract][Full Text] [Related]
20. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.
Zhao J; Wang Q; Deng X; Qian J; Tian Z; Liu Y; Li M; Zeng X
Pharmacol Ther; 2022 Nov; 239():108192. PubMed ID: 35461923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
